← SS Innovations International Inc. Common Stock overview

SS Innovations International Inc. Common Stock vs Guangzhou Wondfo Biotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

SS Innovations International Inc. Common Stock (SSII)

Q3 2026
▲3

SSII's surgical robot adoption accelerates; losses and financing remain the drag

  • Installed base and procedure volumes keep climbing SSi Mantra systems installed rose to 244 by late September, up 45% from end-2025, with 14,503 cumulative procedures and 195 telesurgeries. More machines placed and more surgeries done means more recurring revenue and proof the robot works, which supports the stock.

    This is the core demand engine behind SSII's growth story this period.

  • Record quarterly sales and a beat on installations Q2 revenue hit $13.9 million, up 39% year over year, with 30 systems installed versus the 25 analysts expected and procedures up 143%. Beating expectations on both sales and placements tells investors the business is scaling faster than thought, lifting the stock.

    It shows the financial results that validate the adoption trend.

  • New markets and training widen the runway SSII launched Sri Lanka's first robotic cardiac program, added programs in Colombia and India, and graduated 33 surgeons from seven countries in its first cardiac training class. Training doctors and opening new countries builds future demand and locks in the SSi Mantra ecosystem.

    Geographic and clinical expansion is a fresh driver of future sales.

  • Strong growth but still losing money and needing cash Zacks started coverage with a Neutral rating, noting first-half revenue of $25 million and gross profit of $12.4 million, but also a $6.2 million net loss, reliance on outside financing, and tough competition. Growth is real, but profits and funding needs cap the upside for now.

    It is the main counterweight investors must weigh against the growth story.

August 2026
▲3

SSII's surgical robot adoption accelerates; losses and financing remain the drag

  • Installed base and procedure volumes keep climbing SSi Mantra systems installed rose to 244 by late September, up 45% from end-2025, with 14,503 cumulative procedures and 195 telesurgeries. More machines placed and more surgeries done means more recurring revenue and proof the robot works, which supports the stock.

    This is the core demand engine behind SSII's growth story this period.

  • Record quarterly sales and a beat on installations Q2 revenue hit $13.9 million, up 39% year over year, with 30 systems installed versus the 25 analysts expected and procedures up 143%. Beating expectations on both sales and placements tells investors the business is scaling faster than thought, lifting the stock.

    It shows the financial results that validate the adoption trend.

  • New markets and training widen the runway SSII launched Sri Lanka's first robotic cardiac program, added programs in Colombia and India, and graduated 33 surgeons from seven countries in its first cardiac training class. Training doctors and opening new countries builds future demand and locks in the SSi Mantra ecosystem.

    Geographic and clinical expansion is a fresh driver of future sales.

  • Strong growth but still losing money and needing cash Zacks started coverage with a Neutral rating, noting first-half revenue of $25 million and gross profit of $12.4 million, but also a $6.2 million net loss, reliance on outside financing, and tough competition. Growth is real, but profits and funding needs cap the upside for now.

    It is the main counterweight investors must weigh against the growth story.

Latest
▲3

SSII's surgical robot adoption accelerates; losses and financing remain the drag

  • Installed base and procedure volumes keep climbing SSi Mantra systems installed rose to 244 by late September, up 45% from end-2025, with 14,503 cumulative procedures and 195 telesurgeries. More machines placed and more surgeries done means more recurring revenue and proof the robot works, which supports the stock.

    This is the core demand engine behind SSII's growth story this period.

  • Record quarterly sales and a beat on installations Q2 revenue hit $13.9 million, up 39% year over year, with 30 systems installed versus the 25 analysts expected and procedures up 143%. Beating expectations on both sales and placements tells investors the business is scaling faster than thought, lifting the stock.

    It shows the financial results that validate the adoption trend.

  • New markets and training widen the runway SSII launched Sri Lanka's first robotic cardiac program, added programs in Colombia and India, and graduated 33 surgeons from seven countries in its first cardiac training class. Training doctors and opening new countries builds future demand and locks in the SSi Mantra ecosystem.

    Geographic and clinical expansion is a fresh driver of future sales.

  • Strong growth but still losing money and needing cash Zacks started coverage with a Neutral rating, noting first-half revenue of $25 million and gross profit of $12.4 million, but also a $6.2 million net loss, reliance on outside financing, and tough competition. Growth is real, but profits and funding needs cap the upside for now.

    It is the main counterweight investors must weigh against the growth story.

Guangzhou Wondfo Biotech Co Ltd (300482.CS)

Q3 2026
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.

August 2026
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.

Latest
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.